Customize your JAMA Network experience by selecting one or more topics from the list below.
In this issue of JAMA, we are pleased to publish the names of the 2704 peer reviewers who completed reviews of manuscripts in 2018.1 We extend our sincere appreciation to all reviewers for their thoughtful, insightful, and scholarly evaluation of manuscripts. Their substantive comments and suggestions are an indispensable aspect of the scientific peer review and publication process, helping to ensure the validity and quality of published articles. We express our appreciation and gratitude to all reviewers for these important contributions to articles published in JAMA.
We also extend our sincere thanks to all authors who submitted manuscripts for consideration for publication in JAMA. In 2018, authors submitted a total of 7245 manuscripts, including 4398 research reports and 467 randomized clinical trials (Table). Of the 158 published Original Investigations, 75 were randomized clinical trials. We appreciate that authors have the confidence and trust in JAMA to submit their most important research reports for evaluation and consideration for publication. The quality and importance of these reports is reflected in our current impact factor of 47.7.
In addition, many authors have taken advantage of the opportunity for them to designate at the time of submission that if their manuscript is not accepted by JAMA, it could be considered for referral to one of the 12 other journals in the JAMA Network, including our newest journal, JAMA Network Open. We express our appreciation to all authors who submitted manuscripts to JAMA and look forward to receiving additional manuscripts from you.
In addition, we thank all who read, access, use, listen to, watch, and learn from our content in any format and venue. We continue to find new ways to distribute our content and make useful information readily available for all who access our publications. For example, visual abstracts are now available for many clinical trials, online commenting is available for Viewpoints, and the number of videos accompanying articles has doubled.
The reach of JAMA has continued to diversify and increase substantially, well beyond the 286 000 weekly recipients of the print journal, and includes more than a million subscribers to electronic alerts for each new issue table of contents and for online first articles, more than 750 000 social media followers, approximately 31 million views of full-text articles (PDF or HTML) per year on the JAMA website, and an additional 19 million views of abstracts only. The entire JAMA Network had more than 118 million total website views (full-text, PDF, and abstract only) and 2.3 million podcast downloads in 2018.
We are committed to transparency and continue to inform authors and readers about various JAMA and JAMA Network policies that affect biomedical publishing. Recent editorials have focused on conflict of interest, team science, and scientific misconduct.2-4 We will continue to publish editorials about various editorial policies that are of importance to the scientific community.
We are honored to have the opportunity to serve the clinical, scientific, and academic communities who interact with JAMA as reviewers and authors, and all who experience and learn from JAMA content as readers. We appreciate your contributions and involvement in helping us fulfill JAMA’s mission “to promote the science and art of medicine and the betterment of the public health.”
We will continue to pursue and publish the best research articles and most useful clinical material possible, and we will continue to develop creative content and innovative ways to deliver information efficiently, effectively, and enjoyably.
Corresponding Author: Phil B. Fontanarosa, MD, MBA, JAMA (Phil.Fontanarosa@jamanetwork.org).
Conflict of Interest Disclosures: None reported.
Fontanarosa PB, Bauchner H, Golub RM. Thank You to Peer Reviewers, Authors, and Readers of JAMA. JAMA. 2019;321(11):1057–1058. doi:10.1001/jama.2019.1465
Browse and subscribe to JAMA Network podcasts!
Create a personal account or sign in to: